|
Video: What is a Stock Split?
|
|
BioXcel Therapeutics is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. Co.'s two key clinical development programs are BXCL501, an investigational, proprietary, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. According to our BioXcel Therapeutics stock split history records, BioXcel Therapeutics has had 0 splits. | |
|
BioXcel Therapeutics (BTAI) has 0 splits in our BioXcel Therapeutics stock split history database.
Looking at the BioXcel Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BioXcel Therapeutics shares, starting with a $10,000 purchase of BTAI, presented on a split-history-adjusted basis factoring in the complete BioXcel Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/09/2018 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$11.00 |
|
End price/share: |
$2.71 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-75.36% |
|
Average Annual Total Return: |
-20.43% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,464.43 |
|
Years: |
6.13 |
|
|
|
|
|